|
1
|
de Groot P and Munden RF: Lung cancer
epidemiology, risk factors, and prevention. Radiol Clin North Am.
50:3017–876. 2012. View Article : Google Scholar
|
|
2
|
Kosacka M and Jankowska R: The
epidemiology of lung cancer. Pneumonol Alergol Pol. 75:76–80.
2007.(In Polish). PubMed/NCBI
|
|
3
|
Radziszewska A, Karczmarek-Borowska B,
Gradalska-Lampart M and Filip AA: Epidemiology, prevention and risk
morbidity factors for lung cancer. Pol Merkur Lekarski. 38:113–118.
2015.(In Polish). PubMed/NCBI
|
|
4
|
Steliga MA and Dresler CM: Epidemiology of
lung cancer: Smoking, secondhand smoke, and genetics. Surg Oncol
Clin N Am. 20:605–618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tabchi S, Kassouf E, Rassy EE, Kourie HR,
Martin J, Campeau MP, Tehfe M and Blais N: Management of stage III
non-small cell lung cancer. Semin Oncol. 44:163–177. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Abuaku BK, Mensah BA, Ofori MF,
Myers-Hansen J, Derkyi-Kwarteng AN, Essilfie F, Dokurugu M, Amoakoh
E, Koram KA and Ghansah A: Efficacy of artesunate/amodiaquine in
the treatment of uncomplicated malaria among children in Ghana. Am
J Trop Med Hyg. 97:690–695. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Roussel C, Caumes E, Thellier M, Ndour PA,
Buffet PA and Jaureguiberry S: Artesunate to treat severe malaria
in travellers: review of efficacy and safety and practical
implications. J Travel Med. doi:10.1093/jtm/taw093. PubMed/NCBI
|
|
8
|
Jauréguiberry S, Thellier M, Ndour PA,
Ader F, Roussel C, Sonneville R, Mayaux J, Matheron S, Angoulvant
A, Wyplosz B, et al French Artesunate Working Group, :
Delayed-onset hemolytic anemia in patients with travel-associated
severe malaria treated with artesunate, France, 2011–2013. Emerg
Infect Dis. 21:804–812. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Raffray L, Receveur MC, Beguet M, Lauroua
P, Pistone T and Malvy D: Severe delayed autoimmune haemolytic
anaemia following artesunate administration in severe malaria: A
case report. Malar J. 13:3982014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rolling T, Agbenyega T, Krishna S,
Kremsner PG and Cramer JP: Delayed haemolysis after artesunate
treatment of severe malaria - review of the literature and
perspective. Travel Med Infect Dis. 13:143–149. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Greenshields AL, Fernando W and Hoskin DW:
The anti-malarial drug artesunate causes cell cycle arrest and
apoptosis of triple-negative MDA-MB-468 and HER2-enriched SK-BR-3
breast cancer cells. Exp Mol Pathol. 107:10–22. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang N, Chen H, Teng Y, Ding X, Wu H and
Jin X: Artesunate inhibits proliferation and invasion of mouse
hemangioendothelioma cells in vitro and of tumor growth
in vivo. Oncol Lett. 14:6170–6176. 2017.PubMed/NCBI
|
|
13
|
Zheng L and Pan J: The anti-malarial drug
artesunate blocks Wnt/β-catenin pathway and inhibits growth,
migration and invasion of uveal melanoma cells. Curr Cancer Drug
Targets. 18:988–998. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Verma S, Das P and Kumar VL:
Chemoprevention by artesunate in a preclinical model of colorectal
cancer involves down regulation of β-catenin, suppression of
angiogenesis, cellular proliferation and induction of apoptosis.
Chem Biol Interact. 278:84–91. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vandewynckel YP, Laukens D, Geerts A,
Vanhove C, Descamps B, Colle I, Devisscher L, Bogaerts E, Paridaens
A, Verhelst X, et al: Therapeutic effects of artesunate in
hepatocellular carcinoma: Repurposing an ancient antimalarial
agent. Eur J Gastroenterol Hepatol. 26:861–870. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jeong DE, Song HJ, Lim S, Lee SJ, Lim JE,
Nam DH, Joo KM, Jeong BC, Jeon SS, Choi HY, et al: Repurposing the
anti-malarial drug artesunate as a novel therapeutic agent for
metastatic renal cell carcinoma due to its attenuation of tumor
growth, metastasis, and angiogenesis. Oncotarget. 6:33046–33064.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim C, Lee JH, Kim SH, Sethi G and Ahn KS:
Artesunate suppresses tumor growth and induces apoptosis through
the modulation of multiple oncogenic cascades in a chronic myeloid
leukemia xenograft mouse model. Oncotarget. 6:4020–4035. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rasheed SA, Efferth T, Asangani IA and
Allgayer H: First evidence that the antimalarial drug artesunate
inhibits invasion and in vivo metastasis in lung cancer by
targeting essential extracellular proteases. Int J Cancer.
127:1475–1485. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang L, Qian H, Sha M, Luan Z, Lin M,
Yuan D, Li X, Huang J and Ye L: Downregulation of HOTAIR expression
mediated anti-metastatic effect of artesunate on cervical cancer by
inhibiting COX-2 expression. PLoS One. 11:e01648382016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Alenzi FQ: Links between apoptosis,
proliferation and the cell cycle. Br J Biomed Sci. 61:99–102. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cvejic D, Selemetjev S, Savin S, Paunovic
I and Tatic S: Changes in the balance between proliferation and
apoptosis during the progression of malignancy in thyroid tumours.
Eur J Histochem. 53:65–71. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu L, Zuo LF, Zuo J and Wang J:
Artesunate induces apoptosis and inhibits growth of Eca109 and
Ec9706 human esophageal cancer cell lines in vitro and in
vivo. Mol Med Rep. 12:1465–1472. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Duma N, Santana-Davila R and Molina JR:
Non-small cell lung cancer: Epidemiology, screening, diagnosis, and
treatment. Mayo Clin Proc. 94:1623–1640. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
von Hagens C, Walter-Sack I, Goeckenjan M,
Osburg J, Storch-Hagenlocher B, Sertel S, Elsässer M, Remppis BA,
Edler L, Munzinger J, et al: Prospective open uncontrolled phase I
study to define a well-tolerated dose of oral artesunate as add-on
therapy in patients with metastatic breast cancer (ARTIC M33/2).
Breast Cancer Res Treat. 164:359–369. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang Z, Wang C, Wu Z, Xue J, Shen B, Zuo
W, Wang Z and Wang SL: Artesunate suppresses the growth of
prostatic cancer cells through inhibiting androgen receptor. Biol
Pharm Bull. 40:479–485. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li Q, Ni W, Deng Z, Liu M, She L and Xie
Q: Targeting nasopharyngeal carcinoma by artesunate through
inhibiting Akt/mTOR and inducing oxidative stress. Fundam Clin
Pharmacol. 31:301–310. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cui C, Feng H, Shi X, Wang Y, Feng Z, Liu
J, Han Z, Fu J, Fu Z and Tong H: Artesunate down-regulates
immunosuppression from colorectal cancer Colon26 and RKO cells in
vitro by decreasing transforming growth factor β1 and
interleukin-10. Int Immunopharmacol. 27:110–121. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rassias DJ and Weathers PJ: Dried leaf
Artemisia annua efficacy against non-small cell lung cancer.
Phytomedicine. 52:247–253. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang Y, Wu N, Wu Y, Chen H, Qiu J, Qian X,
Zeng J, Chiu K, Gao Q and Zhuang J: Artesunate induces
mitochondria-mediated apoptosis of human retinoblastoma cells by
upregulating Kruppel-like factor 6. Cell Death Dis. 10:8622019.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang N, Zeng GZ, Yin JL and Bian ZX:
Artesunate activates the ATF4-CHOP-CHAC1 pathway and affects
ferroptosis in Burkitts lymphoma. Biochem Biophys Res Commun.
519:533–539. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li Y, Mu W, Ren J, Wuermanbieke S, Wahafu
T, Ji B, Ma H, Amat A, Zhang K and Cao L: Artesunate alleviates
interleukin-1β-induced inflammatory response and apoptosis by
inhibiting the NF-κB signaling pathway in chondrocyte-like ATDC5
cells, and delays the progression of osteoarthritis in a mouse
model. Int J Mol Med. 44:1541–1551. 2019.PubMed/NCBI
|
|
33
|
Chen X, Zhang XL, Zhang GH and Gao YF:
Artesunate promotes Th1 differentiation from CD4+ T cells to
enhance cell apoptosis in ovarian cancer via miR-142. Braz J Med
Biol Res. 52:e79922019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen P, Gu WL, Gong MZ, Wang J and Li DQ:
Artesunate decreases beta-catenin expression, cell proliferation
and apoptosis resistance in the MG-63 human osteosarcoma cell line.
Cell Physiol Biochem. 43:1939–1949. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nunes JJ, Pandey SK, Yadav A, Goel S and
Ateeq B: Targeting NF-kappa B signaling by artesunate restores
sensitivity of castrate-resistant prostate cancer cells to
antiandrogens. Neoplasia. 19:333–345. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jing W, Shuo L, Yingru X, Min M, Runpeng
Z, Jun X and Dong H: Artesunate promotes sensitivity to sorafenib
in hepatocellular carcinoma. Biochem Biophys Res Commun. 519:41–45.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu L, Zuo LF and Guo JW: Reversal of
multidrug resistance by the anti-malaria drug artesunate in the
esophageal cancer Eca109/ABCG2 cell line. Oncol Lett. 6:1475–1481.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang L, Liu L, Wang J and Chen Y:
Inhibitory effect of artesunate on growth and apoptosis of gastric
cancer cells. Arch Med Res. 48:623–630. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang L, Liu L, Chen Y, Du Y, Wang J and
Liu J: Correlation between adenosine triphosphate (ATP)-binding
cassette transporter G2 (ABCG2) and drug resistance of esophageal
cancer and reversal of drug resistance by artesunate. Pathol Res
Pract. 214:1467–1473. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang P, Luo HS, Li M and Tan SY:
Artesunate inhibits the growth and induces apoptosis of human
gastric cancer cells by downregulating COX-2. OncoTargets Ther.
8:845–854. 2015. View Article : Google Scholar
|
